Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Thomsen, Henrik F., Gasparyan, Samvel B., Furberg, Julie F., Tasto, Christoph, Rethemeier, Nicole, Schloemer, Patrick, Wang, Tuo, Jongs, Niels, Du, Yu, Greene, Tom
Format: Preprint
Veröffentlicht: 2025
Schlagworte:
Online-Zugang:https://arxiv.org/abs/2504.05909
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1866916844353355776
author Thomsen, Henrik F.
Gasparyan, Samvel B.
Furberg, Julie F.
Tasto, Christoph
Rethemeier, Nicole
Schloemer, Patrick
Wang, Tuo
Jongs, Niels
Du, Yu
Greene, Tom
author_facet Thomsen, Henrik F.
Gasparyan, Samvel B.
Furberg, Julie F.
Tasto, Christoph
Rethemeier, Nicole
Schloemer, Patrick
Wang, Tuo
Jongs, Niels
Du, Yu
Greene, Tom
contents Win statistics based methods have gained traction as a method for analyzing Hierarchical Composite Endpoints (HCEs) in randomized clinical trials, particularly in cardiovascular and kidney disease research. HCEs offer several key advantages, including increased statistical power, mitigation of competing risks, and hierarchical ranking of clinical outcomes. While, as summary measures, the win ratio (WR) along with the Net Benefit (NB) and the Win Odds (WO) provide a structured approach to analyzing HCEs, several concerns regarding their interpretability remain. In this paper, we present known issues with the WR using simple examples designed to explore the implications for the clinical interpretability of the treatment effect measure in the chronic kidney disease setting. Specifically, we discuss the challenge of defining an appropriate estimand in the context of HCEs using the WR, the difficulties in formulating a relevant causal question underlying the WR, and the dependency of the WR on the variance of its components, which complicates its role as an effect measure. Additionally, we highlight the non-collapsibility and non-transitivity of the WR, further complicating its interpretation. While the WR remains a valuable tool in clinical trials, its inherent limitations must be acknowledged to ensure its proper use in regulatory and clinical decision-making.
format Preprint
id arxiv_https___arxiv_org_abs_2504_05909
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Interpretational challenges of the Win Ratio in analyzing Hierarchical Composite Endpoints in Chronic Kidney Disease
Thomsen, Henrik F.
Gasparyan, Samvel B.
Furberg, Julie F.
Tasto, Christoph
Rethemeier, Nicole
Schloemer, Patrick
Wang, Tuo
Jongs, Niels
Du, Yu
Greene, Tom
Methodology
Win statistics based methods have gained traction as a method for analyzing Hierarchical Composite Endpoints (HCEs) in randomized clinical trials, particularly in cardiovascular and kidney disease research. HCEs offer several key advantages, including increased statistical power, mitigation of competing risks, and hierarchical ranking of clinical outcomes. While, as summary measures, the win ratio (WR) along with the Net Benefit (NB) and the Win Odds (WO) provide a structured approach to analyzing HCEs, several concerns regarding their interpretability remain. In this paper, we present known issues with the WR using simple examples designed to explore the implications for the clinical interpretability of the treatment effect measure in the chronic kidney disease setting. Specifically, we discuss the challenge of defining an appropriate estimand in the context of HCEs using the WR, the difficulties in formulating a relevant causal question underlying the WR, and the dependency of the WR on the variance of its components, which complicates its role as an effect measure. Additionally, we highlight the non-collapsibility and non-transitivity of the WR, further complicating its interpretation. While the WR remains a valuable tool in clinical trials, its inherent limitations must be acknowledged to ensure its proper use in regulatory and clinical decision-making.
title Interpretational challenges of the Win Ratio in analyzing Hierarchical Composite Endpoints in Chronic Kidney Disease
topic Methodology
url https://arxiv.org/abs/2504.05909